Raptamer Therapeutics

Raptamer Therapeutics is a biotechnology company focused on developing next-generation aptamer-based therapies using its proprietary Raptamer platform. The company's technology utilizes uniquely modified, synthetic DNA molecules that offer superior binding affinity and specificity compared to traditional antibodies and standard aptamers. Raptamer's lead programs include Raptamer-Drug Conjugates (RapDCs) targeting Interleukin-1 receptor accessory protein (IL1RAP) for Ewing sarcoma and osteosarcoma, as well as programs in non-small cell lung cancer and head and neck cancer. By integrating peptides and oligonucleotides, the company creates modular therapeutic candidates that can be rapidly developed and scaled for precision medicine applications. Supported by Fannin Partners, the company leverages its platform to address high unmet needs in oncology and infectious diseases.